MedTrace Logo

Real-world Comparative Effectiveness of Apixaban Versus Vitamin K Antagonist

NCT02687854 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 18591

Last updated 2017-04-05

No results posted yet for this study

Summary

To obtain a better understanding on the comparative effectiveness of apixaban versus VKA (Vitamin K antagonist) for stroke prevention in patients with NVAF (Non-valvular atrial fibrillation) in a real-life setting.

Conditions

Interventions

DRUG

Apixaban

As prescribed by treating physicians

DRUG

Vitamin K antagonist

As prescribed by treating physicians

Sponsors & Collaborators

Principal Investigators

  • Bayer Study Director · Bayer

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-02-12
Primary Completion
2016-03-01
Completion
2016-03-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02687854 on ClinicalTrials.gov